Gun companies made more than $1 billion from assault weapon sales over a decade, House panel says

Gun companies made more than  billion from assault weapon sales over a decade, House panel says


Fire arms are seen at the Bobâs Little Sport Gun Shop in the town of Glassboro, New Jersey, United States on May 26, 2022. 

Tayfun Coskun | Anadolu Agency | Getty Images

Major gun manufacturers have made over $1 billion in the last decade selling military-style assault weapons, according to an investigation by the House Committee on Oversight and Reform.

A memo from the panel outlines manufacturers’ revenue and marketing strategies for assault-style weapons, focusing on the the gun brands used in recent mass shootings. The release came ahead of a Wednesday hearing on the role of the firearms industry in pervasive gun violence in the United States.

Earnings from assault weapons more than doubled for brands like Smith & Wesson, Sturm Ruger and Daniel Defense between 2019 and 2021, according to House findings. Sturm Ruger CEO Christopher Killoy, and Daniel Defense CEO Marty Daniel are set to testify at Wednesday’s hearing. Smith & Wesson CEO Mark Smith was invited but won’t attend.

At the hearing, Chairwoman Rep. Carolyn B. Maloney, D-N.Y., announced that the committee will issue subpoenas to Smith & Wesson and other manufacturers.

The committee also provided estimated assault weapon revenues for these companies since 2012, the year a gunman killed 20 children and six adults at Sandy Hook Elementary School in Connecticut:

  • Smith & Wesson: $695 million
  • Sturm Ruger: $514 million
  • Daniel Defense: $528 million
  • SIG Sauer: Refused to report
  • Bushmaster: $2.9 million (2021 only)

The number of recent mass shooting deaths was also listed for each company, with assault weapons from all five brands used in at least two recent massacres. The gunman who killed 19 children and two teachers in May at Robb Elementary School in Uvalde, Texas, used a weapon made by Daniel Defense.

The brands themselves do not track deaths, injuries or crimes that involve their weapons. Sig Sauer told the committee that it does “not have the means” to track deaths. Sturm Ruger said it learns of incidents through its “customer service department,” the media or from occasional lawsuits.

The hearing comes just after California Gov. Gavin Newsom recently signed a law allowing citizens affected by gun violence to sue manufacturers.

The committee also focused on marketing tactics, including Smith & Wesson advertisements that mimic first-person shooter video games and a Sig Sauer weapon sold as an “apex predator.”

House Democrats are pushing to vote on an assault weapons ban later this week. If passed, the bill is unlikely to make it through the Senate.

Smith & Wesson, Sig Sauer and Sturm Ruger did not immediately respond to a request for comment.



Source

RFK Jr. removes all members of CDC panel advising U.S. on vaccines
Health

RFK Jr. removes all members of CDC panel advising U.S. on vaccines

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. testifies before the Senate Committee on Appropriations hearing on the Department of Health and Human Services budget, on Capitol Hill in Washington, D.C., U.S., May 20, 2025. Ken Cedeno | Reuters Health and Human Services Secretary Robert F. Kennedy Jr. on Monday said he […]

Read More
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Health

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

The Food and Drug Administration on Monday approved Merck’s shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead […]

Read More
JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More